Daxxify (daxibotulinumtoxinA-lanm) is the longest-lasting cosmetic neurotoxin approved by the FDA. Its median duration in pivotal trials was 24 weeks — roughly 6 months — roughly double the 3-to-4-month window typical of Botox, Dysport, Xeomin, and Jeuveau. Some patients maintained visible improvement for up to 9 months.
But "median" is not a guarantee. Duration depends on the area treated, the dose used, your muscle strength, your metabolism, and whether the use is on-label (frown lines) or off-label (forehead, crow's feet, masseter). This article breaks down what the SAKURA clinical trials actually found, how Daxxify's timeline compares to other neurotoxins, and what factors change your personal result.
What the clinical trials found
The FDA approved Daxxify in September 2022 based on the SAKURA Phase 3 program — three studies (SAKURA 1, 2, and 3) enrolling more than 2,700 patients and approximately 4,200 treatments. All three studies treated moderate-to-severe glabellar lines (the vertical "11" lines between the eyebrows) with 40 units of Daxxify.
Key findings from the SAKURA trials:
- Median duration of "none or mild" severity: 24 weeks (approximately 6 months) across all three studies. This was the co-primary endpoint in SAKURA 1 and SAKURA 2, and the result was highly consistent: 24.0 weeks in SAKURA 1, 23.9 weeks in SAKURA 2, and 24 weeks in the open-label SAKURA 3.
- Median time to return to baseline: up to 28 weeks in the pooled analysis — meaning some residual effect lingered beyond the 6-month clinical threshold.
- ≥2-grade improvement at Week 4: approximately 74% of patients achieved this threshold in both SAKURA 1 (73.6%) and SAKURA 2 (74.0%), as assessed by both investigators and patients.
- Duration beyond 6 months: about half of treated patients still had no or minor frown lines at the 6-month mark. Approximately 10% maintained visible improvement through 9 months.
- Safety: the adverse event profile was comparable to other botulinum toxin type A products. The most common treatment-related events were headache (6.4%), injection site pain (3.7%), and eyelid drooping (ptosis). Notably, the side effects did not last longer despite the longer clinical effect.
An important caveat: the SAKURA trials only treated glabellar lines with a fixed 40-unit dose. The study population was predominantly female and white. Results for other facial areas, other doses, or other demographic groups come from clinical experience rather than controlled trials.
How Daxxify's timeline compares
| Timeline | Daxxify | Botox | Dysport | Xeomin | Jeuveau |
|---|---|---|---|---|---|
| Onset | 1–2 days | 5–7 days | 2–3 days | 3–5 days | 3–5 days |
| Peak effect | 2–4 weeks | 2–4 weeks | 2 weeks | 2–4 weeks | 2–3 weeks |
| Median duration (glabellar) | ~24 weeks | ~12–16 weeks | ~12–16 weeks | ~12–16 weeks | ~12–16 weeks |
| Treatment frequency per year | ~2 | ~3–4 | ~3–4 | ~3–4 | ~3–4 |
The core difference is the peptide exchange technology (Peptide Exchange Technology, or PXT). Daxxify is the only neurotoxin stabilized with a novel proprietary peptide rather than human serum albumin. The peptide is thought to facilitate faster binding to nerve receptors (explaining the rapid onset) and more stable attachment (explaining the extended duration). Daxxify is also vegan — it contains no human- or animal-derived proteins.
On-label vs. off-label: duration differs
The 24-week median duration is specifically for glabellar lines at 40 units — the FDA-approved indication. Providers also use Daxxify off-label for:
- Forehead lines: a Phase 2 study (presented at MauiDerm 2020) and real-world data published in PMC reported a median time to loss of "none or mild" forehead line severity of up to 20.9 weeks with 32 units — shorter than the 24-week glabellar median. The frontalis is a thin, highly active muscle, and this difference is consistent with what clinicians see across all neurotoxins: forehead duration is typically less than glabellar duration.
- Crow's feet (lateral canthal lines): smaller muscles, potentially slightly longer duration per unit of effect.
- Masseter (jawline slimming): large, powerful muscle. Higher doses are common. Duration data comes from clinical experience rather than trials.
- Hyperhidrosis (excessive sweating): some providers report extended duration compared to Botox for this indication, but published evidence is limited.
For any off-label area, your provider is extrapolating from the glabellar data and their own clinical experience. The 6-month median should be treated as a reasonable benchmark, not a floor or a ceiling.
Factors that change your personal duration
Several variables affect how long Daxxify lasts for you specifically:
- Muscle mass and strength. Larger, stronger muscles (the masseter, the frontalis in men) metabolize neurotoxin faster. Patients with pronounced muscle activity may see duration closer to 4–5 months rather than 6.
- Metabolism. Patients who exercise intensely, have high metabolic rates, or are younger tend to process neurotoxins faster.
- Dose. Higher doses generally produce longer-lasting effects, but the relationship is not linear, and higher doses carry higher risk of unwanted spread or ptosis. Your provider determines dose based on your anatomy, not a universal formula.
- Treatment area. Areas with more movement (around the mouth, forehead expressiveness) tend to wear off sooner.
- Previous neurotoxin use. Patients who have developed neutralizing antibodies to other botulinum toxins may also have reduced response to Daxxify, though the SAKURA trials found no evidence of immunogenicity within the study timeframe. The minimum recommended interval between treatments is 3 months.
- Number of prior treatments. Some evidence across neurotoxins suggests that repeated treatment over time can produce longer-lasting results as the treated muscles thin (atrophy) from disuse.
Cost implications of longer duration
Daxxify typically costs more per treatment session than Botox — often 20–40% more per unit. But because you may need only two sessions per year instead of three or four, the annual cost can be comparable or even lower.
Approximate annual math (US averages):
| Daxxify | Botox | |
|---|---|---|
| Sessions per year (glabellar) | ~2 | ~3–4 |
| Cost per session | ~$500–$800 | ~$300–$600 |
| Annual total (estimated) | ~$1,000–$1,600 | ~$900–$2,400 |
These ranges vary widely by geography, provider, and how many areas are treated. The per-session cost of Daxxify is higher, but the frequency is lower. Whether that is a net saving depends on your individual duration.
When Daxxify may not be the right choice
Longer duration is not universally desirable:
- First-time neurotoxin patients may prefer starting with a shorter-acting product (Botox, Xeomin) in case they dislike the result. With Daxxify, an unfavorable outcome lasts longer.
- Patients who like to adjust frequently — changing dose, placement, or technique between sessions — may find 6 months too long between opportunities to refine.
- Patients with a history of ptosis or asymmetry from neurotoxins should be cautious, since any adverse effect will also persist longer.
- Pregnancy and breastfeeding: no adequate controlled studies. The label advises caution. This is true of all botulinum toxins.
- Patients taking blood thinners or with neuromuscular conditions (myasthenia gravis, Lambert-Eaton syndrome) should discuss risks with their provider. These are precautions common to all botulinum toxin products.
Storage and formulation differences
Daxxify can be stored at room temperature (20–25°C / 68–77°F) before reconstitution — shared with Xeomin, but unlike Botox, Dysport, and Jeuveau, which require refrigeration. It is supplied as a lyophilized powder that must be reconstituted with sterile saline before injection, similar to other neurotoxins. The room-temperature storage simplifies inventory logistics for practices but does not affect clinical outcomes for the patient.
What to ask your provider
If you are considering Daxxify, these questions are worth asking:
- What dose do you plan to use for each area, and why?
- Which areas will you treat on-label vs. off-label?
- If I do not like the result, how long will I need to wait before it resolves?
- What is your experience specifically with Daxxify, not just neurotoxins in general?
- What is the total cost per session, and how does that compare to your Botox pricing over a full year?
Sources
Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58. https://pubmed.ncbi.nlm.nih.gov/31609882/
Fabi SG, Cohen JL, Green LJ, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. Dermatol Surg. 2021;47(1):48-54. https://pubmed.ncbi.nlm.nih.gov/32773446/
Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from SAKURA 1 and SAKURA 2. J Am Acad Dermatol. 2020;82(4):838-845. https://pubmed.ncbi.nlm.nih.gov/31791824/
DaxibotulinumtoxinA-Ianm. StatPearls. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK594233/
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC8648634/
DAXI (DaxibotulinumtoxinA) – An Innovative Approach for Frown Lines. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC10103897/
DAXXIFY (daxibotulinumtoxinA-lanm) injection, full prescribing information. Revance Therapeutics, Inc. https://www.daxxify.com/
American Society of Plastic Surgeons. How does Daxxify compare to Botox? https://www.plasticsurgery.org/news/articles/how-does-daxxify-compare-to-botox
Achieving Durable Forehead Line Outcomes With DaxibotulinumtoxinA: Early Experience in Real-World Clinical Practice. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11140817/
DAXXIFY prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761127s002lbl.pdf
